Ayala Pharmaceuticals Stock Book Value Per Share
| ADXSDelisted Stock | USD 1.38 0.34 32.69% |
Ayala Pharmaceuticals fundamentals help investors to digest information that contributes to Ayala Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ayala OTC Stock. The fundamental analysis module provides a way to measure Ayala Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ayala Pharmaceuticals otc stock.
Ayala |
Ayala Pharmaceuticals OTC Stock Book Value Per Share Analysis
Ayala Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Ayala Pharmaceuticals Book Value Per Share | 0.32 X |
Most of Ayala Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ayala Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Ayala Pharmaceuticals is about 0.32 times. This is 118.82% lower than that of the Healthcare sector and 100.13% lower than that of the Biotechnology industry. The book value per share for all United States stocks is 99.98% higher than that of the company.
Ayala Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ayala Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Ayala Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ayala Pharmaceuticals by comparing valuation metrics of similar companies.Ayala Pharmaceuticals is currently under evaluation in book value per share category among its peers.
Ayala Fundamentals
| Return On Equity | -41.98 | ||||
| Return On Asset | -24.13 | ||||
| Current Valuation | (25.1 M) | ||||
| Shares Outstanding | 145.64 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Number Of Shares Shorted | 39.89 K | ||||
| Price To Earning | (1.62) X | ||||
| Price To Book | 5.25 X | ||||
| Price To Sales | 990.34 X | ||||
| Revenue | 250 K | ||||
| Gross Profit | 3.24 M | ||||
| EBITDA | (15.31 M) | ||||
| Net Income | (16.24 M) | ||||
| Cash And Equivalents | 28.15 M | ||||
| Cash Per Share | 15.50 X | ||||
| Total Debt | 19 K | ||||
| Current Ratio | 15.64 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (16.04 M) | ||||
| Short Ratio | 0.95 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Number Of Employees | 14 | ||||
| Beta | 2.28 | ||||
| Market Capitalization | 247.58 M | ||||
| Total Asset | 169.04 M | ||||
| Retained Earnings | (354.94 M) | ||||
| Working Capital | 132.17 M | ||||
| Current Asset | 159.88 M | ||||
| Current Liabilities | 27.71 M |
About Ayala Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ayala Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ayala Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ayala Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Ayala OTC Stock
If you are still planning to invest in Ayala Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ayala Pharmaceuticals' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |